Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01795040
Other study ID # OMEGA-Study
Secondary ID
Status Recruiting
Phase N/A
First received February 16, 2013
Last updated March 14, 2017
Start date September 2010
Est. completion date May 2017

Study information

Verified date March 2017
Source University of Cologne
Contact Manfred Doepfner, Prof. Dr.
Email Manfred.doepfner@uk-koeln.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The efficacy of PUFAs (as nutritional supplement) in/for pre-school children with ADHS symptoms will be evaluated in a randomised controlled doubleblind trail with children aged 3-6 years.


Description:

The study aims at the reduction of hyperactivity, inattention and impulsivity in pre-school children aged 3-6 years, visiting a preschool, and the prevention of clinical ADHD symptoms. The 3-6 years old children will be identified by a combined parent and teacher rating ADHD-symptoms questionnaire (FBB-ADHS-V). Children with ADHD symptoms >90th percentile will participate in a following diagnostic process. The children (n = 150) will be randomised doubleblind to a control group (taking every day four capsules Equazen eye q, containing 400 mg fish oil and 100mg evening primrose oil - EPA (372mg), DHA (116mg), GLA (40mg) and vitamin E (7.2 mg) ) or placebo group. The study is divided into two phases with four months each. After unblinding after the first phase pre-school children taking placebo receive Omega-3/Omega-6 Fatty Acids. Children (n = 75) taking verum during first four months will be randomised doubleblind to verum or placebo. In this way the progress of the behaviour symptoms will be evaluated after a significant period of time (eigth months). Clinical examination (questionnaires, intelligence test, medical examination) and evaluation of ADHD symptoms through parents and teachers with several questionnaires will be used before beginning, after four months and after eight months. In addition the pre-school children will be taken a blood sample (finger prick test) to measure the omega-3/omega-6 fatty acids levels. Additionally regular phone calls will be implemented. Medical examinations and meetings will taken place if required. If symptoms increase, children will be treated medical and/ or psychotherapeutically.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date May 2017
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 3 Years to 6 Years
Eligibility Inclusion Criteria:

- Age: 3 - 6 years

- Visit of a preschool (Kindergarten)

- Parents have a command of the German language

- Screening score >90th percentile in a combined parent and teacher screening questionnaire

Exclusion Criteria:

- Hypersensitivity or inability to components of the study product (fish oil, primrose oil, natural strawberry flavouring, bovine gelatine)

- Consumption of omega fatty acids preparation

- Consumption of fish oil-capsules

Study Design


Related Conditions & MeSH terms

  • Children With ADHD Symptoms >90th Percentile (FBB-ADHS-V); no Beginning or Completion of Psychotherapeutically or Psychopharmalogical Treatment During the Study

Intervention

Dietary Supplement:
omega-3/omega-6 fatty acids (PUFAs)
Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid

Locations

Country Name City State
Germany Department of Child and Adolescent Psychiatry at the University Cologne Cologne

Sponsors (1)

Lead Sponsor Collaborator
University of Cologne

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other finger prick test to measure the PUFA blood concentration It will taken a blood sample (finger prick test) to measure the omega-3/omega-6 fatty acids levels. Change from pre- assessment to post assessment four months after treatment begin
Primary Change in Symptom Checklist for pre-school children with ADHD symptoms (FBB-ADHS-V) total score rated by parents and teachers The FBB-ADHS-V Questionnaire is a developed parent and teacher rating scale which assesses several factors of hyperactivity, impulsivity and inattention problems in pre-school or at home. Change from pre- assessment to post assessment four months after treatment begin and to post assessment eight months after treatment begin
Secondary Change in ODD symptoms -parent/ teacher rated (FBB-ADHD-V) Change from pre- assessment to post assessment four months after treatment begin and to post assessment eight months after treatment begin
Secondary Change in Child Behavior Checklist (CBCL) and Teacher Report Form (TRF) The CBCL and the TRF are well evaluated rating scales for the assessement of a broad spectrum of child behavioral and emotional problems as perceived by parents and teachers respectively Change from pre- assessment to post assessment four months after treatment begin.
Secondary Diagnostic checklist for ADHD (DCL-ADHS) and diagnostic checklist for odd (DCL-SSV) The DCL-ADHD and the DCL-ODD are external assessment questionnaires. Parents were asked 18 questions to hyperactivity, impulsivity and inattention by the rater or to symptom criteria for ODD. Change from pre- assessment to post assessment four months after treatment begin and to post assessment eight months after treatment begin
Secondary Change in intelligence: Sequential & Simultaneous Processing, Achievement (K-ABC) The Kaufman Assessment Battery for Children (K-ABC) is a standardized test that assesses intelligence and achievement in children aged 2;6 to 12;6 years. It is comprised of four global test scores that include: sequential processing scales, simultaneous processing scales, achievement scales and mental processing composite. There is an additional nonverbal scale. Change from pre- assessment to post assessment four months after treatment begin.